{'fraction_non_alphanumeric': 0.04915912031047866, 'fraction_numerical': 0.04980595084087969, 'mean_word_length': 4.625454545454545, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical efficacy of anti-reflux therapy combined with tiotropium bromide in COPD patients with GERD

AIM: To investigate the clinical efficacy of anti-reflux therapy combined with tiotropium bromide in chronic obstructive pulmonary disease(COPD) patients with gastroesophageal reflux disease(GERD).METHODS: Forty-eight GERD patients who were treated at our hospital from January 2014 to December 2014 were included and randomly divided into either an observation group or a control group, with 24 patients in each group. The observation group was given esomeprazole, mosapride and tiotropium bromide, and the control group was only given tiotropium bromide. GERD-Q score, number of acute episodes of COPD and clinical efficacy were compared between the two groups. R E S U LT S : After 1 year of treatment, GERD-Q score significantly decreased in the observation group(15.23 ± 3.75 vs 9.83 ± 2.65, P 0.05); the number of acute episodes of COPD significantly decreased in both the observation group(1.59 ± 0.34 vs 1.08 ± 0.30) and control group(1.60 ± 0.41 vs 1.33 ± 0.31), and the decrease was more significant in the than observation group than in the control group(1.08 ± 0.30 vs 1.33 ± 0.31, P 0.05), but the rate of GERD symptom improvement was better in the observation group(95.83% vs66.67%, P < 0.01).CONCLUSION: Anti-reflux treatment combined with tiotropium bromide for COPD patients with GERD is feasible, and it can effectively improve GERD-Q score, decrease the number of acute episodes of COPD and has a significant curative effect.